HappycapyGuide

By Connie · Last reviewed: April 2026 — pricing & tools verified · AI-assisted, human-edited · This article contains affiliate links. We may earn a commission at no extra cost to you if you sign up through our links.

How to Use AI for an Endocrinology Practice in 2026: Diabetes + Thyroid + Adrenal + Obesity, CGM Triage, GLP-1 Step Therapy, and the Owner Scorecard

Published 2026-06-04 · 14 min read

TL;DR — endocrinology practice AI stack for 2026. Point AI at six bottlenecks: (1) new-patient intake with structured chief-complaint, family hx, med list, and prior-lab synthesis, (2) ambient-scribed endo SOAP with CPT 99202-99215 + 95249-95251 CGM interpretation + 95250-95251 personal CGM + 99091 RPM + 99453-99457 RPM, (3) CGM + AID + insulin-pump data triage with TIR + TBR + GMI + CV + sensor-compliance flags, (4) thyroid + adrenal + pituitary + reproductive endo + bone-metabolism + obesity workup templates, (5) GLP-1 + tirzepatide + semaglutide + obesity prior-auth + step-therapy appeal pack, (6) HIPAA-safe recall + measurement-based-care via PHQ-9 + GAD-7 + WAI-DM + diabetes-distress + ePROM. Wrap it in a compliance floor: HIPAA + 42 CFR Part 2 + FDA 510(k) AI-SaMD + ADA 2024 + AACE + Endocrine Society + ATA + state AI scribe rules CA AB 3030 + TX SB 815 + UT HB 452 + IL HB 1806 + CMS MIPS MVP Diabetes + Cardiovascular Care 2025 + AKS / Stark on diagnostics + DME pump + CGM + insulin-vendor rebate + FTC Endorsement Guides + Fake Reviews Rule 16 CFR 465. Target owner KPI: chart-closure under 30 minutes per visit, GLP-1 prior-auth approval over 75 percent, TIR over 70 percent in CGM cohort, CGM-cohort A1C reduction over 0.5 percent in 6 months, 5-star Google profile, weekly 60-minute scorecard.

The 7-layer endocrinology practice AI stack (2026)

LayerExamplesOwner
Intake + portal + schedulingPhreesia AI, NexHealth, Klara, Doctible, Solutionreach, RevenueWell, Weave AI, Luma Health, RelatientOffice manager
Ambient endo SOAP + EHRDeepScribe, Abridge, Suki Assistant, Nuance DAX Copilot, Heidi, Freed, Sunoh.ai + Epic Beaker / Healthy Planet, Oracle Cerner, athenaOne, eCW, NextGen, Modernizing Medicine EMA, Greenway IntergyClinician + scribe lead
CGM + AID + insulin-pump triageDexcom Clarity AI, Libre LibreView, Medtronic CareLink, Tidepool, Glooko, Tandem Source, Omnipod View, Diasend, Tandem t:slim X2, Insulet Omnipod 5, Beta Bionics iLet, Tidepool Loop, Vertex VX-880Diabetes care + education specialist (DCES)
Imaging + lab decision supportACR TI-RADS Calculator, ATA Bethesda, Aidoc, Rad AI, Heuro, Riverain Technologies, Quantib, EndoBase, EndoNote, Genoox Franklin AI, Tempus Labs Endo, Karius, CarisClinician + lab director
Prior-auth + denial appealCoverMyMeds, Glidian, Surescripts Prior Auth, Office Ally, Availity, Waystar, Myndshft, Banjo Health, Cohere HealthPractice administrator
Compliance + AI policy + privacyDrata, Vanta, Compliancy Group, MedTrainer, HIPAA One, Keragon HIPAA-aligned automations, Health-IT.gov SAFER, BAA tracker, FSMB AI PolicyCompliance officer
Recall + measurement-based care + reviewsOwl Insights, Mirah, Greenspace, NeuroFlow, Rcopia + Surescripts, Klara, Weave AI, Phreesia, BirdEye, Podium, NiceJob, SwellCare coordinator

10 copy-paste prompts for endocrinology teams

1) New-patient intake synthesis

You are the endocrinology intake AI. From the patient-completed Phreesia / NexHealth / portal questionnaire + uploaded outside records, output a structured intake brief for the clinician: - Chief complaint + duration + recent change (weight gain or loss, fatigue, polyuria + polydipsia, palpitations, heat or cold intolerance, hair changes, menstrual changes, sexual dysfunction, hirsutism, acne, mood, sleep) - Past medical hx + current diagnoses (DM type, HTN, dyslipidemia, OSA, MAFLD, prior thyroid, adrenal, pituitary, gonadal, bone, obesity-medical history) - Surgical hx (thyroidectomy, adrenalectomy, hypophysectomy, bariatric, oophorectomy, orchiectomy, parathyroidectomy) - Family hx with age of onset (T1DM, T2DM, MODY, MEN1 + MEN2A + MEN2B, FAP, von Hippel-Lindau, autoimmune polyglandular syndrome, hereditary cancer) - Medication list with dose + duration + adherence + side effect (insulin regimens, GLP-1, tirzepatide, SGLT2, metformin, sulfonylurea, levothyroxine, methimazole, PTU, hydrocortisone, fludrocortisone, testosterone, estrogen, progesterone, GnRH agonist, somatropin, sandostatin, denosumab, teriparatide, romosozumab) - Prior labs trended (HbA1c, fasting + post-prandial glucose, lipid, TSH + free T4 + free T3 + anti-TPO + anti-TG + TSI, ACTH + cortisol AM + 24-hr UFC, aldosterone + renin, DHEA-S, plasma metanephrines, IGF-1, prolactin, FSH + LH + estradiol or testosterone, 25-OH vit D, PTH, calcium + phosphorus, alkaline phosphatase, magnesium, ferritin) - Prior imaging (thyroid US, neck CT, adrenal CT, MRI sella, DXA, bone-age x-ray) - Red flags: severe hypo or DKA hx, hypertensive emergency on adrenal incidentaloma, visual-field cut on pituitary mass, hypercalcemia symptomatic, pheochromocytoma triad - Patient goals + barriers + insurance coverage notes Output a 1-page brief flagging the top 3 items for the clinician to address first.

2) Ambient endocrinology SOAP with CPT capture

You are the ambient AI scribe for an endocrinology visit. From the audio + clinician dictation, output the SOAP: S - subjective: chief complaint + interval history + symptom diary + medication adherence + lifestyle (diet, exercise, sleep, stress, alcohol, tobacco) O - objective: vital signs (BP, HR, weight, BMI, waist circumference), focused PE (thyroid palpation, eye exam for Graves orbitopathy, skin for acanthosis or striae, neuro for diabetic neuropathy + Tinel + monofilament + vibration + reflexes, orthostatic vitals if adrenal insufficiency suspected), recent labs + CGM + DXA + thyroid US + MRI sella A - assessment: ICD-10 differential (E10 T1DM, E11 T2DM, E13 MODY + secondary, E03 hypothyroidism, E05 hyperthyroidism, E04 nontoxic goiter, E22 hyperpituitarism, E23 hypopituitarism, E24 Cushing, E27 adrenal disorders, E28 ovarian, E29 testicular, E66 obesity, E83 mineral metabolism, E55 vit D deficiency, M81 osteoporosis without fracture, M80 with pathological fracture) P - plan: order set, prescription changes, prior-auth flags, lab + imaging schedule, follow-up cadence, patient education + DCES referral + nutrition + behavioral health Capture CPT 99202-99215 E and M, 95249-95251 personal CGM interpretation, 95250 patient-supplied CGM, 99091 RPM data review, 99453-99457 RPM setup + monitoring, 90832-90838 add-on if behavioral health, G0108-G0109 DSMT, S9452-S9455 MNT, 96125 cognitive testing, 96156-96171 HBAI add-on Flag any element missing for level-of-service support. Sign-off required by the clinician before the note is filed.

3) CGM + AID 14-day data triage

You are the CGM + AID triage AI. Pull the 14-day download from Dexcom Clarity / Libre LibreView / Medtronic CareLink / Tidepool / Glooko / Tandem Source / Omnipod View. Compute and flag: - Time in range (TIR) 70-180 mg/dL — goal over 70 percent for most adults, over 50 percent for high-risk older adults per ATTD 2019 + ADA 2024 - Time above range 180-250 (TAR1) and over 250 (TAR2) — goal under 25 percent and under 5 percent - Time below range 54-70 (TBR1) and under 54 (TBR2) — goal under 4 percent and under 1 percent - Glucose Management Indicator (GMI) and estimated A1C correlation - Coefficient of variation (CV) — goal under 36 percent - Sensor wear time — goal over 70 percent - Severe hypo events (under 54 mg/dL for over 15 minutes) — flag for immediate review - Suspected pump occlusion or AID failure (sustained hyperglycemia with no insulin response) - Dawn phenomenon pattern (overnight rise greater than 30 mg/dL between 3am-7am) - Post-prandial spike pattern (peak rise greater than 80 mg/dL within 2 hours) - Pre-meal hypoglycemia or rebound hyperglycemia - Exercise-related lows or highs - Weekend vs weekday pattern - Compare to prior 14-day window — flag any deterioration over 5 percent in TIR Output a 1-page chart for the clinician with red-flagged items at the top. No autonomous insulin or basal-rate change — clinician sign-off required for every titration.

4) GLP-1 + tirzepatide + obesity prior-auth pack

You are drafting a prior-auth pack for [DRUG] (semaglutide Wegovy or Ozempic, tirzepatide Zepbound or Mounjaro, dulaglutide Trulicity, liraglutide Saxenda or Victoza). Capture from the chart: - Diagnosis: ICD-10 E11 T2DM with HbA1c value, or E66.01 morbid obesity BMI 40+, or E66.9 obesity BMI 30+ with comorbidity (HTN, dyslipidemia, OSA, MAFLD, T2DM, established CVD) - Prior failed therapies with dose, duration, and reason for failure (metformin, SGLT2, sulfonylurea, lifestyle, phentermine, topiramate, naltrexone-bupropion, orlistat) - Documented 6-month lifestyle intervention with weight, BMI, A1C trends - Cardiovascular indication if applicable (Wegovy MACE-reduction approval March 2024 for established CVD + obesity) - Contraindications ruled out (personal or family hx MTC, MEN2, severe gastroparesis, pancreatitis hx) - Clinical justification with FDA label + ADA 2024 + AACE 2024 + Endocrine Society Obesity Pharmacotherapy 2023 - Plan-specific formulary check (Medicare Part D coverage limited to CVD indication, Medicaid varies by state, commercial varies by employer) - Step-therapy override request if patient has documented intolerance or contraindication to step drug - Appeal letter template if denial received with peer-to-peer request and external review escalation Output the prior-auth letter for clinician review and signature. Track approval rate, appeal-overturn rate, turnaround in days, and patient out-of-pocket in the scorecard.

5) Thyroid nodule + Bethesda + TI-RADS workflow

You are managing a thyroid nodule. From the US report and prior labs, structure the workup per ATA 2015 + ACR TI-RADS: - Calculate TI-RADS score (composition + echogenicity + shape + margin + echogenic foci) — TR1 benign, TR2 not suspicious, TR3 mildly suspicious, TR4 moderately suspicious, TR5 highly suspicious - FNA threshold: TR3 over 2.5 cm, TR4 over 1.5 cm, TR5 over 1.0 cm — exceptions for symptomatic or compressive - TSH check first — if low, RAIU scan to rule out functional adenoma before FNA - Bethesda category from FNA cytology: I non-diagnostic, II benign, III AUS or FLUS, IV follicular neoplasm, V suspicious for malignancy, VI malignant - Molecular testing on Bethesda III-IV (Afirma GSC, ThyroSeq v3, ThyGeNEXT + ThyraMIR) for risk stratification - Surgery referral threshold: Bethesda V or VI, Bethesda IV with concerning molecular profile, compressive or substernal goiter - Active surveillance protocol per ATA + AACE 2022 if low-risk papillary microcarcinoma under 1 cm + favorable location - TSH suppression target post-thyroidectomy: TSH 0.1-0.5 for low-risk, less than 0.1 for intermediate-high-risk per ATA - Levothyroxine dose calculation: 1.6 mcg/kg/day starting, adjust based on TSH every 6-8 weeks Output the workup plan with timeline, lab schedule, imaging, and surgical referral if applicable.

6) Adrenal incidentaloma + functional workup

You are working up an adrenal incidentaloma per AACE 2023 + Endocrine Society 2016 + ESE 2023: - Imaging characterization: size, Hounsfield units (less than 10 HU on non-contrast CT typically benign adenoma), washout (over 60 percent absolute or over 40 percent relative on contrast washout) - Functional workup screen: 1-mg overnight dexamethasone suppression test for autonomous cortisol secretion (cortisol over 1.8 mcg/dL post-dex is mild autonomous cortisol secretion, over 5.0 mcg/dL is overt Cushing) - Plasma free metanephrines or 24-hr urine fractionated metanephrines for pheochromocytoma — required on every adrenal mass - Aldosterone-to-renin ratio if hypertension or hypokalemia - DHEA-S if virilization or feminization - Size threshold for surgery: over 4 cm with imaging concern, or any functional mass, or growth over 0.5-1.0 cm in 6-12 months - Repeat imaging at 6-12 months for non-functional under 4 cm with benign features - MEN2 screen (RET) and Lynch screen if pheochromocytoma identified - Pre-op alpha-blockade for pheochromocytoma 7-14 days with phenoxybenzamine or doxazosin, then beta-blockade 2-3 days Output the 6-month workup + surveillance plan with lab + imaging schedule.

7) Pituitary mass + visual-field + hormone panel

You are working up a pituitary mass per Endocrine Society 2011 + 2023 + Pituitary Society 2024: - Anterior pituitary panel: TSH + free T4, ACTH + AM cortisol, FSH + LH + estradiol or testosterone, prolactin, IGF-1 - Posterior: morning urine osmolality, sodium, water-deprivation test if DI suspected - MRI sella with and without gadolinium with thin cuts through the sellar region - Visual field testing (Humphrey 24-2 or 30-2) if mass abuts or compresses optic chiasm - Functional adenoma classification: prolactinoma (prolactin over 250 ng/mL with macro), GH-secreting (acromegaly with elevated IGF-1 + non-suppressed GH on OGTT), ACTH-secreting (Cushing disease with elevated 24-hr UFC + non-suppressed dex), TSH-secreting (rare, central hyperthyroidism with elevated TSH and free T4), gonadotroph or non-functioning - Treatment: dopamine agonist (cabergoline) for prolactinoma first-line, transsphenoidal surgery for GH and Cushing and TSH and non-functioning with mass effect, somatostatin analog (octreotide LAR, lanreotide, pasireotide) for residual acromegaly or Cushing, pegvisomant for refractory acromegaly, mifepristone or osilodrostat or metyrapone for medical Cushing - Hormone replacement post-surgery: hydrocortisone, levothyroxine, sex steroids, growth hormone (where indicated), desmopressin if DI - Surveillance: annual MRI sella, annual hormone panel, every-2-year visual field if anatomic risk Output the workup + surgical-referral letter to neurosurgery if applicable.

8) Diabetes + obesity step-therapy + denial appeal letter

You are drafting a peer-to-peer + external review appeal for a denied [DRUG] prior auth. Capture: - Patient demographics + insurance + plan + denial reason verbatim - Diagnosis with ICD-10 + HbA1c + BMI + comorbidities - Prior failed therapies with dose + duration + reason for failure (intolerance, contraindication, inadequate response) - Step-therapy override justification: contraindication, prior failure on plan-required step drug, anticipated harm - Clinical evidence: FDA label + ADA 2024 + AACE 2024 + Endocrine Society Obesity Pharmacotherapy 2023 + cardiovascular outcome trial citations (LEADER, REWIND, SUSTAIN-6, STEP-HFpEF, SELECT, SURMOUNT-1, SURMOUNT-2) - State step-therapy reform statute citation if applicable (CA SB 313, NY S2849A, TX SB 875, FL HB 1003, IL SB 2541, plus 30+ other states with reform laws) - Peer-to-peer request with proposed times - External review escalation request with state DOI form citation if peer-to-peer denied - Patient impact statement: disease progression risk, hospitalization risk, end-organ damage risk Output the appeal letter for clinician review + signature. Track approval rate + days-to-decision.

9) HIPAA-safe recall + measurement-based care

You are running the recall + measurement-based care program. For each patient on registry: - Diabetes registry: A1C every 3 months if not at goal, every 6 months if at goal; lipid annual; UACR + eGFR annual; foot exam annual; eye exam annual or every 2 years per ADA; flu + pneumococcal + COVID + RSV vaccines per CDC - Thyroid registry: TSH every 6-12 months on stable levothyroxine, every 6-8 weeks during dose adjustment, US every 1-2 years for monitored nodule - Adrenal incidentaloma registry: imaging per protocol (6-12 months for benign features, sooner for concerning), annual functional screen if mild autonomous cortisol secretion - Pituitary registry: annual MRI sella, annual hormone panel, visual field per anatomic risk - Bone metabolism registry: DXA every 1-2 years on therapy, P1NP + CTX at 3 + 12 months on bisphosphonate or anabolic - PRO administration: PHQ-9 + GAD-7 + WAI-DM diabetes-distress + DDS + Audit-C + obesity-impact-of-weight-on-quality-of-life IWQOL-Lite + Hypoglycemia Confidence Scale every 3-6 months - HIPAA-safe outreach: SMS + email + portal + patient-preferred channel; opt-in confirmation; quiet hours 8am-9pm; do-not-contact override; PHI minimum-necessary - TCPA + state mini-TCPA + FCC 2024 one-to-one consent + state two-party recording consent if voice Output a recall list with priority order + scripted message + escalation path if no response in 14 days.

10) Owner monthly scorecard

Produce a 1-page owner monthly scorecard: - Volume: new patients, follow-ups, no-show rate, recall-completion rate, telehealth percent - Productivity: RVU per clinician-hour, chart-closure time per visit, ambient-scribe adoption rate, PRO completion rate - Quality: A1C cohort improvement, TIR cohort improvement, GLP-1 prior-auth approval rate + appeal-overturn rate, thyroid + adrenal + pituitary protocol-adherence - Cash: collections, AR aging, denial rate, CPT 99202-99215 + 95249-95251 + 99091 + 99453-99457 + DSMT G0108-G0109 + MNT S9452-S9455 capture rate - Compliance: BAA inventory, AI policy attestation, state AI scribe consent + disclosure, FSMB AI policy alignment, MIPS MVP Diabetes + Cardiovascular Care 2025 quality measures, AKS + Stark on diagnostics + DME + insulin-pump + CGM-vendor + insulin-rebate, DEA + state PDMP if controlled-substance prescribing - People: open clinician roles, DCES headcount, MA + clinical-staff retention, 90-day onboard completion, AI-tool adoption rate - Customer: new reviews (5-star + sub-4 count), GBP rating trend, NPS, PRO score trend Flag the 3 highest-priority issues for next month's action. No more.

Compliance floor (2026) — do not ship without these

60-day AI rollout for a 1-3 endocrinologist practice

  1. Days 1-5: Phreesia + NexHealth + portal intake live. Patient-completed structured questionnaire pulled into chart.
  2. Days 6-10: Ambient endo SOAP (DeepScribe / Abridge / Suki / DAX / Heidi / Freed / Sunoh) live; clinician sign-off workflow.
  3. Days 11-15: CGM + AID + insulin-pump triage (Prompt 3) live. Dexcom + Libre + Medtronic + Tidepool + Glooko + Tandem + Omnipod data flow into AI triage queue.
  4. Days 16-25: Thyroid + adrenal + pituitary workup templates (Prompts 5-7) live. Bone metabolism + reproductive endo templates added.
  5. Days 26-35: GLP-1 + tirzepatide + obesity prior-auth pack (Prompt 4) live. Step-therapy + denial appeal letter (Prompt 8) ready.
  6. Days 36-45: HIPAA-safe recall + measurement-based-care (Prompt 9) digital. PRO administration via Owl + Mirah + Greenspace + portal.
  7. Days 46-55: AI policy + BAA inventory + state AI consent + medical-board AI guidance audit. FSMB Model Policy alignment review.
  8. Days 56-60: Owner monthly scorecard (Prompt 10) live. First monthly review meeting. CMS MIPS MVP Diabetes + Cardiovascular Care 2025 quality-measure capture audit.

8 mistakes that sink endocrinology AI projects

FAQ

Can AI safely triage continuous-glucose-monitor and automated-insulin-delivery data without the endocrinologist reading every report?

AI can pre-triage the dataset and surface what the clinician must review, but it cannot replace clinical judgment on titration. The standard workflow: pull 14-day CGM downloads from Dexcom Clarity / Libre LibreView / Medtronic CareLink / Tidepool / Glooko / Tandem Source / Omnipod View, compute time-in-range (TIR) per ATTD 2019 + ADA 2024 targets (TIR 70-180 mg/dL goal over 70 percent for most adults, TIR over 50 percent for high-risk older adults), time-below-range (TBR less than 4 percent under 70, less than 1 percent under 54), GMI, coefficient-of-variation goal under 36 percent. AI flags high-priority charts (severe hypo events, sensor compliance under 70 percent, suspected pump occlusion, dawn phenomenon, post-prandial spikes over 80 mg/dL). The endocrinologist or DCES reviews flagged charts and signs off on every titration order — no autonomous insulin or basal-rate change without clinician review per FDA 510(k) AI-SaMD framework + state medical-board AI guidance.

What does the GLP-1 + tirzepatide + obesity step-therapy + prior-auth landscape actually look like in 2026?

Coverage is fragmented. Medicare Part D still does not cover GLP-1s (Wegovy, Zepbound) for obesity alone — only when paired with an FDA-approved cardiovascular indication (Wegovy approved for MACE reduction in obesity + established CVD March 2024). Medicaid coverage varies by state (16+ states cover for obesity as of 2026). Commercial: most plans require prior auth with documented BMI 30+ or 27+ with comorbidity, 6-month lifestyle trial, step through phentermine + topiramate or naltrexone-bupropion, and contract carve-outs by employer. The appeal pack should cite FDA labels, ADA 2024 + AACE 2024 + Endocrine Society Obesity Pharmacotherapy 2023 guidelines, and patient-specific HbA1c, weight, BMI, comorbidity. AI drafts the prior-auth letter + denial appeal in 4-6 minutes pulling from the chart; the endocrinologist signs. Track approval rate, appeal-overturn rate, and turnaround in the scorecard.

How do I document AI use to satisfy state medical-board AI scribe and AI clinical-decision-support rules?

Eight states now have explicit AI rules in 2025-2026: CA AB 3030 (effective Jan 2025) + TX SB 815 (effective Sep 2025) + UT HB 452 AI Mental Health Policy Act + IL HB 1806 (effective Jan 2026) + NY S1331A pending + CO AI Act 2024 + WA + DC. Plus FSMB Model Policy on AI in Medical Practice 2024. Floor: (1) patient-facing AI generative outputs include clear disclosure (CA AB 3030 requires the disclaimer in any communication), (2) AI scribe outputs are reviewed and signed by the licensed clinician before becoming part of the record (no autonomous chart entry), (3) AI clinical decision support is FDA-cleared 510(k) for AI-SaMD where the use is decision-support (not just informational), (4) document the AI tool, version, training-data scope, and intended use in the practice's written AI policy + BAA, (5) capture written patient consent for AI scribe per state requirement (some states implied, some explicit), (6) annual audit of AI-generated content for accuracy + hallucination rate. Tools like DeepScribe, Abridge, Suki, Nuance DAX Copilot, Heidi, Freed, and Sunoh.ai all carry BAAs and are FDA-aligned where required.

What is the right thyroid + adrenal + pituitary workup template that AI can draft?

AI can draft the structured workup pulling from the chief complaint, family history, medication list, and prior labs. Standard frames: (1) Thyroid nodule per ATA 2015 Bethesda + ACR TI-RADS 5 categories with FNA threshold by size + TR score, (2) hypothyroidism per ATA 2014 with TSH + free T4 + anti-TPO + anti-TG + ratio of T3:T4 if Hashimoto suspected, (3) hyperthyroidism per ATA 2016 with TSH-receptor Ab + TSI + RAIU scan + Graves vs nodular vs thyroiditis, (4) adrenal incidentaloma per AACE 2023 + Endocrine Society 2016 with 1-mg overnight dexamethasone suppression + plasma metanephrines + aldosterone-renin ratio + DHEA-S + size + Hounsfield units, (5) pituitary mass per Endocrine Society 2011 + 2023 with full anterior + posterior pituitary panel + MRI sella + visual field if optic chiasm proximity, (6) pheochromocytoma per Endocrine Society 2014 with plasma free metanephrines + 24-hr urine + clonidine suppression if equivocal, (7) Cushing syndrome per Endocrine Society 2008 with 1-mg DST + 24-hr UFC + late-night salivary cortisol + low-dose DST. AI drafts; clinician confirms differential + orders.

What ROI should a 1-3 endocrinologist practice expect from AI in 90 days?

Realistic: (1) 30-50 percent reduction in chart-closure time via ambient endo SOAP (DeepScribe, Abridge, Suki, Nuance DAX Copilot, Heidi, Freed) — 60-90 minutes per clinician per day reclaimed, (2) 25-40 percent faster CGM + AID review with AI pre-triage flagging only high-priority charts for clinician sign-off, (3) 40-60 percent faster prior-auth letter and appeal drafting on GLP-1, tirzepatide, semaglutide, dulaglutide, ozempic-vs-wegovy, growth hormone, IGF-1, hydrocortisone, levothyroxine special formulation, (4) 20-30 percent improvement in TIR for type 1 + type 2 patients enrolled in AI-augmented CGM titration program (per real-world studies on AID + remote-patient-monitoring 2024-2025), (5) measurable reduction in no-show rate via AI recall + reminder, (6) explicit documentation trail for state medical-board + CMS MIPS MVP Diabetes + Cardiovascular Care 2025 quality-measure compliance. Dollars show up in scorecard (Prompt 10): visit volume, RVU per clinician-hour, prior-auth approval rate, GLP-1 appeal turnaround, CGM TIR cohort improvement.

Sources + further reading

Related guides

SharePost on XLinkedIn
—Was this helpful?

Get the best AI tools tips — weekly

Honest reviews, tutorials, and Happycapy tips. No spam.

You might also like

How-To Guide

How to Use AI for an OB/GYN Practice in 2026: ACOG/SMFM Practice Bulletins, USPSTF + ACS, HIPAA Reproductive Health 2024 Final Rule, MIPS MVP Promoting Wellness in Women's Health, Prior-Auth + Denial Appeal, and the Owner Scorecard

14 min

How-To Guide

How to Use AI for a Junk Removal Business in 2026: DOT FMCSA, EPA RCRA + UWR + CAA §608, State Solid Waste + E-Waste, OSHA Lifting + Bloodborne, FTC Cooling-Off + TCPA, and the Owner Scorecard

14 min

How-To Guide

How to Use AI for an Elder Law Firm in 2026: ABA Op 512, Medicaid 5-Year Lookback 42 USC §1396p + DRA 2005, SNT (d)(4)(A)/(C) + ABLE + SECURE 2.0 §125, VA Pension 38 CFR 3.274/3.275 + 14.629, Guardianship + Capacity per UGCOPAA, and the Owner Scorecard

14 min

How-To Guide

How to Use AI for a Physical Therapy Practice in 2026: APTA Code of Ethics, Medicare Therapy Cap + KX + Targeted MR, MIPS MVP Rehabilitative Support, State PT Compact, and the Owner Scorecard

14 min

Comments